Med spa semaglutide programs are legal when a licensed prescriber runs them, not the med spa as a business. A med spa entity cannot prescribe anything. A physician, nurse practitioner, or physician assistant licensed in the patient's state can evaluate the patient, decide semaglutide is appropriate, and write the prescription, and the med spa provides the setting, the brand, and the patient experience around it. The harder questions in 2026 are which drug you use and how you source it. FDA declared the semaglutide shortage resolved in February 2025 and the tirzepatide shortage resolved in December 2024, which ended the broad shortage-based pathway for copying those drugs through compounding. As of September 2026, FDA has also proposed removing semaglutide and tirzepatide from the 503B bulks list. A durable med spa GLP-1 program is built around FDA-approved products (Wegovy, Zepbound) plus narrowly justified, patient-specific compounding, with a real medical director and at-home follow-up handled through telehealth.
This guide covers who can prescribe, the compounding picture, 503A vs 503B sourcing, safety screening, economics, and how to run follow-up remotely. This is general information, not legal or medical advice. Confirm your specific setup with healthcare counsel in your state.
Key takeaways
- A med spa as a business entity cannot prescribe semaglutide; only a licensed physician, NP, or PA acting within their state scope of practice can, after an appropriate evaluation.
- FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, which ended the broad shortage-based justification for compounding copies of those drugs.
- As of September 2026, FDA has proposed (April 30, 2026) excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list; a final determination had not been announced at the time of writing.
- In-office administration from stock generally runs through a 503B outsourcing facility, while take-home, patient-specific prescriptions run through a 503A pharmacy or a retail pharmacy for branded products.
- GLP-1 care is a months-long program of titration, side-effect management, and refills, and telehealth is the most practical way for a med spa to handle that follow-up between visits.
Can med spas prescribe semaglutide?
No, not as a business. Prescribing is an act of medicine, and only licensed clinicians practice medicine. What a med spa can do is host a medical weight-loss service in which a licensed prescriber does the clinical work.
In practice, three things have to be true:
- A licensed prescriber evaluates each patient. That is a physician, NP, or PA licensed in the state where the patient is located, working within that state's scope-of-practice and supervision or collaboration rules. Some states require a good faith examination before treatment, and many have specific rules for when that exam can happen by telehealth.
- The ownership and control structure is lawful. Many states restrict the corporate practice of medicine, which means a non-physician owner cannot employ physicians or control clinical decisions. Med spas in those states typically use a physician-owned professional entity alongside a management services organization (MSO) that handles the non-clinical business. Our MSO and corporate practice of medicine guide walks through the structure.
- There is genuine medical oversight. A "medical director" who signs paperwork and never reviews charts is precisely what state boards look for. Our guide to finding a medical director for a med spa covers what real oversight looks like.
Nurses and aestheticians can often administer injections under a valid order, depending on the state, but they cannot originate the prescription. Rules differ meaningfully between states, so map the specific requirements for each location before launch.
Compounded semaglutide vs Wegovy and Zepbound: what changed?
For most of 2022 through early 2025, GLP-1 medications appeared on FDA's drug shortage list. While a drug is in shortage, federal law gives compounders more room to make copies of it, and that is how compounded semaglutide and tirzepatide became the default for many med spas and telehealth brands.
That window has largely closed. Here is the timeline, as of September 2026:
- December 2024: FDA declared the tirzepatide (Mounjaro/Zepbound) shortage resolved.
- February 21, 2025: FDA declared the semaglutide (Ozempic/Wegovy) shortage resolved. It gave 503A pharmacies until April 22, 2025, and 503B outsourcing facilities until May 22, 2025, before ending enforcement discretion tied to the shortage.
- April 30, 2026: FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, stating it did not find sufficient clinical need for outsourcing facilities to compound them from bulk drug substances. The comment period closed June 29, 2026.
- 2025–2026: FDA sent waves of warning letters over how compounded GLP-1s were marketed, especially claims implying compounded products are the same as, or FDA-approved like, the branded drugs.
What that means for a med spa today:
- FDA-approved products are the stable foundation. Wegovy (semaglutide) and Zepbound (tirzepatide) are FDA-approved for chronic weight management. Supply risk is lower now that the shortages are over, and there is no compounding-eligibility question to defend.
- 503A compounding still exists, but narrowly. A 503A pharmacy generally cannot compound products that are "essentially copies" of a commercially available drug. Compounding for a specific patient usually needs a documented clinical reason why the approved product does not work for that patient. "It's cheaper" is not that reason.
- Marketing is a live enforcement area. Do not call compounded products "generic Wegovy," imply FDA approval, or use branded drug names to advertise compounded versions.
For a deeper side-by-side on the tirzepatide version of this question, see compounded tirzepatide vs Zepbound. Whatever you decide, get your pharmacy partner's current compounding position in writing, with a date on it.
Should a med spa use a 503A or 503B pharmacy for GLP-1s?
It depends on where the medication is administered. The two federal compounding categories fit two different operating models, and a med spa GLP-1 program often touches both. Our 503A vs 503B guide covers the full distinction.
| In-office administration | Take-home (at-home injection) | |
|---|---|---|
| Where the dose is given | At the med spa, by a nurse or clinician under a valid order | By the patient at home |
| Typical source | 503B outsourcing facility (office-use stock), or branded product | Retail pharmacy for Wegovy/Zepbound; 503A for patient-specific compounds when clinically justified |
| Prescription needed per dose | Office stock is not tied to a named patient; a valid order and chart entry still are | Yes, a patient-specific prescription |
| Main regulatory watch item | Status of the 503B bulks list proposal for GLP-1s | "Essentially a copy" limits and documented clinical need |
| Visit cadence | Patient returns to the spa for each injection | Remote check-ins plus periodic in-person visits |
| Operational burden on the spa | Inventory, cold storage, administration logs | Prescription routing, shipping, and refill management |
Two notes. First, if FDA finalizes the 503B proposal, compounded office stock for these molecules gets much harder to source, so plan the in-office model around branded products or confirm your 503B partner's status. Second, weekly in-office injections are good for foot traffic but hard for patients to sustain for months. Most programs that last land on a hybrid: in-person start and periodic check-ins, with take-home medication and remote follow-up.
How do you screen patients for a med spa GLP-1 program?
Safety screening is the prescriber's job, but the med spa owns the intake experience that feeds it. A defensible screening flow collects enough to make a real clinical decision and flags anyone who needs a different pathway.
What the intake and prescriber review should cover:
- Eligibility for the indication. Wegovy and Zepbound are labeled for adults with obesity, or overweight with at least one weight-related condition. Document BMI, measured rather than self-reported whenever possible, and relevant conditions.
- Contraindications from the label. Both products carry a boxed warning about thyroid C-cell tumors and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Pregnancy and plans to become pregnant also need to be addressed.
- Risk history. History of pancreatitis, gallbladder disease, diabetic retinopathy, kidney problems, and severe GI disease. Also current medications, especially insulin or sulfonylureas, where hypoglycemia risk rises.
- Eating disorder screening. A med spa's patient mix can include people for whom a weight-loss drug is the wrong answer. Screen for it and have a referral pathway.
- Labs and baseline vitals as the prescriber requires.
- Informed consent that explains side effects, titration, what happens when the drug is stopped, and, if compounded products are used, that they are not FDA-approved.
The dosing risk to design against specifically: FDA has received adverse event reports tied to dosing errors with compounded GLP-1s, often from multidose vials where patients drew the wrong volume. If take-home compounded medication is ever used, dose-in-units instructions, teach-back, and a way for patients to reach someone quickly are non-negotiable.
What do med spa semaglutide program economics look like?
We won't give you a number, because the honest answer varies too much by market, drug choice, and model. The structure of the economics is predictable, though.
Revenue drivers:
- Program fees (consults, monitoring, coaching) rather than drug markup. With branded products, the patient often buys the drug through a pharmacy or manufacturer program, so the med spa earns on the clinical program around it.
- Retention. GLP-1 treatment runs for months. A patient who stays through titration is worth far more than one who drops out after the first month from nausea and no follow-up.
- Cross-sell. Weight-loss patients often become candidates for body contouring, skin tightening, and other aesthetic services as they lose weight. This is why a med spa is a natural home for the program.
Cost drivers:
- Prescriber time, including a medical director and every follow-up visit.
- Pharmacy and inventory (cold storage and waste for in-office stock).
- Compliance: legal review of the structure, consent forms, marketing review, malpractice coverage.
- Patient support. Side-effect questions come in at all hours and cost real staff time.
The margin risk: building the program around compounded pricing that may not be available next quarter. Programs designed around branded products and a sound clinical service tend to be more durable than programs whose whole value proposition was a cheap vial.
How does telehealth handle at-home follow-up?
This is where most med spa GLP-1 programs break. The first visit happens in the spa. Then comes weeks two through sixteen: dose escalations, nausea, constipation, "I missed a dose, what now?", refill timing, and progress checks. Asking patients to drive in for each of those is expensive for them and for your clinical staff.
Telehealth fits naturally here:
- Async check-ins between visits (weight, side effects, adherence) that a prescriber reviews, with escalation to a video visit when something looks off.
- Synchronous visits for dose changes or new symptoms, where state rules or clinical judgment call for them.
- E-prescribing and refills routed to the right pharmacy for the patient's state and product, without the spa handling paperwork.
- Documentation that lands in one chart, so the medical director can actually oversee what is happening.
The build-vs-partner question is the same one every telehealth founder faces. Building your own prescriber network across states, e-prescribing, pharmacy routing, and a HIPAA-compliant platform is a heavy lift for a med spa. A white-label telehealth partner handles that layer under your brand. Our comparison of the best white-label telehealth platforms lays out the options honestly.
Frequently asked questions
Can med spas prescribe semaglutide?
A med spa as a business cannot prescribe semaglutide, because prescribing is the practice of medicine. A licensed physician, nurse practitioner, or physician assistant acting within their state's scope of practice can evaluate the patient and prescribe it within a med spa setting. The legal structure, medical oversight, and exam requirements vary by state.
Is compounded semaglutide still legal for med spas in 2026?
It is much narrower than it was. FDA declared the semaglutide shortage resolved in February 2025, ending the broad shortage-based pathway, and in April 2026 it proposed excluding semaglutide from the 503B bulks list. As of September 2026, 503A patient-specific compounding generally requires a documented clinical reason the FDA-approved product is not suitable. Get a dated written position from your pharmacy partner and counsel.
What is the difference between Wegovy and compounded semaglutide?
Wegovy is an FDA-approved semaglutide product for chronic weight management, manufactured under FDA approval and labeling. Compounded semaglutide is prepared by a pharmacy and is not FDA-approved, so FDA has not reviewed it for safety, effectiveness, or quality. Marketing compounded products as equivalent to Wegovy has drawn FDA warning letters.
Do med spas need a 503A or 503B pharmacy for GLP-1s?
In-office administration from stock generally relies on a 503B outsourcing facility or branded product, while take-home, patient-specific prescriptions go through a 503A pharmacy or retail pharmacy. Many med spas use more than one rail. Watch the status of FDA's proposal on GLP-1s and the 503B bulks list, because it directly affects compounded office stock.
Can a med spa run GLP-1 follow-up through telehealth?
Yes, as long as the prescriber is licensed in the state where the patient is located and follows that state's telehealth and exam rules. Telehealth is well suited to the titration check-ins, side-effect management, and refills that make up most of a GLP-1 program. It also keeps patients engaged between in-person visits.
Add a GLP-1 program without building the medical layer
MyOrbitHealth is white-label telehealth infrastructure for med spas and wellness brands. Your brand stays front and center. We provide the clinical and pharmacy layer: a network of 2,400+ board-certified providers across 38+ specialties in all 50 states, with average response under six minutes during business hours. Orbit Intake handles adaptive screening with red-flag escalation, and OrbitRx routes e-prescriptions via Surescripts to a LegitScript-certified pharmacy network. Book a demo to see how a GLP-1 program would run under your brand.